Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04162210 · OUTCOME

Titers of ADAs Against Belantamab Mafodotin

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Titer
Interval / dispersion
Full Range
Time frame
Up to approximately 263 weeks

What was measured

Serum samples were collected and tested for the presence of antibodies against belantamab mafodotin . Confirmed positive ADA samples were further analyzed to obtain the titer of the antibodies. Titers of anti-drug antibodies against belantamab mafodotin is presented.

Analysis population: Safety Population. Data for only that participant with positive ADA results is presented.

Groups in this outcome

Belantamab Mafodotin

Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin1

Reported measurements

Source class 1
Values in Titer · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin200Not reportedNANAFull range is not evaluable for a single participant. Median value presented here is the actual titer value for this single participant.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Full range is not evaluable for a single participant. Median value presented here is the actual titer value for this single participant.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        200
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
Serum samples were collected and tested for the presence of antibodies against belantamab mafodotin . Confirmed positive ADA samples were further analyzed to obtain the titer of the antibodies. Titers of anti-drug antibodies against belantamab mafodotin is presented.
dispersion Type
Full Range
groups
  1. description
    Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
    id
    OG000
    title
    Belantamab Mafodotin
param Type
MEDIAN
population Description
Safety Population. Data for only that participant with positive ADA results is presented.
reporting Status
POSTED
time Frame
Up to approximately 263 weeks
title
Titers of ADAs Against Belantamab Mafodotin
type
SECONDARY
unit Of Measure
Titer

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice